Gain Therapeutics (GANX) Current Leases (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Current Leases of $116627.0 for Q1 2026, down 21.56% year-over-year from $148674.0 in Q1 2025, and down 2.71% quarter-over-quarter from $119876.0 in Q4 2025.
Gain Therapeutics (GANX) Current Leases (2020 - 2026) Analysis & Trends
Gain Therapeutics' Current Leases history runs 7 years deep, the most recent figure standing at $116627.0 for Q1 2026.
- In Q1 2026, Current Leases fell 21.56% year-over-year to $116627.0; the TTM figure through Mar 2026 stood at $116627.0 (down 21.56% YoY), while the FY2025 annual figure was $119876.0, down 25.5% from the prior year.
- Current Leases for Q1 2026 stood at $116627.0, down from $119876.0 in the prior quarter.
- The five-year high for Current Leases was $235798.0 in Q2 2023, with the low at $115910.0 in Q3 2025.
- The 5-year median for Current Leases is $204569.0 (2024), against an average of $187080.9.
- The sharpest annual moves came in 2022 and 2025: Current Leases surged 83.22% in 2022, then plunged 35.17% in 2025.
- Gain Therapeutics' Current Leases stood at $229080.0 in 2022, then gained by 0.27% to $229693.0 in 2023, then dropped by 29.94% to $160913.0 in 2024, then decreased by 25.5% to $119876.0 in 2025, then slipped by 2.71% to $116627.0 in 2026.
- Business Quant data shows GANX's Current Leases at $116627.0 in Q1 2026, $119876.0 in Q4 2025, and $115910.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | - |
| 10 | Gain Therapeutics | 86.19 Mn | 86.19 Mn | - | 109,428.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 109,428.00 |
| Mar 31, 2026 | 116,627.00 |
| Dec 31, 2025 | 119,876.00 |
| Sep 30, 2025 | 115,910.00 |
| Jun 30, 2025 | 136,320.00 |
| Mar 31, 2025 | 148,674.00 |
| Dec 31, 2024 | 160,913.00 |
| Sep 30, 2024 | 178,781.00 |
| Jun 30, 2024 | 186,846.00 |
| Mar 31, 2024 | 204,569.00 |
| Dec 31, 2023 | 229,693.00 |
| Sep 30, 2023 | 231,164.00 |
| Jun 30, 2023 | 235,798.00 |
| Mar 31, 2023 | 232,507.00 |
| Dec 31, 2022 | 229,080.00 |
| Sep 30, 2022 | 214,971.00 |
| Jun 30, 2022 | 216,180.00 |
| Mar 31, 2022 | 222,467.00 |
| Dec 31, 2021 | 219,137.00 |
| Sep 30, 2021 | 170,271.00 |